EU fines six for pay-for-delay

Share this article:

The European Union is fining drugmakers over efforts to keep generics of the blood-pressure drug perindopril off the market.

Bloomberg reports that the EU has fined six drugmakers, including brand owner Les Laboratories Servier ($451 million) and generic maker Teva ($21 million), over the pay-for-delay strategy which extended the brand's hold on the marketplace.

Bloomberg says the EU's accusations against Servier included making agreements with generics makers to keep generics out of pharmacies and acquiring competing technologies.

Krka Group, Mylan Laboratories, Unichem Laboratories and Lupin Ltd., were also fined.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.